Cell Signaling Technology

Product Pathways - NF-kB Signaling

TWEAK Antibody #4437

Applications Reactivity Sensitivity MW (kDa) Source
W H (M) (Mk) Recombinant 30 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

TWEAK Antibody detects recombinant and transfected levels of TWEAK protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His110 of human Tweak protein. Antibodies were purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from 293 cells, mock transfected (-) or transfected with a construct overerexpressing human TWEAK (+), using TWEAK Antibody.

Western Blotting

Western Blotting

Western blot analysis of recombinant protein containing the extracellular domain of human TWEAK, using TWEAK Antibody.

Background

TWEAK (TNFSF12/Apo-3L) is a member of the TNF superfamily of cytokines that are typically involved in immune regulation, inflammation, and apoptosis (1,2). TWEAK mRNA is expressed in a variety of tissues and cell lines, with higher levels observed in the heart, brain, skeletal muscle and within the immune system (1). Like other family members TWEAK is a type II transmembrane protein that can also be proteolytically processed to form a soluble cytokine. Soluble TWEAK is a weak inducer of apoptosis in some cell lines (1). The receptor for TWEAK, known as TWEAKR or fibroblast growth factor inducible 14 (Fn14), is a relatively small member of the TNF receptor family (3). TWEAK signaling has been associated with apoptosis, proliferation, migration, angiogenesis, and inflammation (4). Recent studies have suggested some therapeutic potential of TWEAK and its receptor signaling in regards to autoimmunity, cancer, and vascular injury (5-8).

  1. Chicheportiche, Y. et al. (1997) J Biol Chem 272, 32401-10.
  2. Marsters, S.A. et al. (1998) Curr Biol 8, 525-8.
  3. Wiley, S.R. et al. (2001) Immunity 15, 837-46.
  4. Wiley, S.R. and Winkles, J.A. (2003) Cytokine Growth Factor Rev 14, 241-9.
  5. Desplat-Jégo, S. et al. (2005) Clin Immunol 117, 15-23.
  6. Mueller, A.M. et al. (2005) J Neuroimmunol 159, 55-65.
  7. Winkles, J.A. et al. (2006) Cancer Lett 235, 11-7.
  8. Ortiz, A. et al. (2009) Cytokine Growth Factor Rev 20, 251-8.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products